Search PubMed⌕ Search

Biomedical subjects

J M Kane

Publications and source records attributed to J M Kane.

At least 199 records · Page 11Linked to original sources
PubMed1982

Prevalence of abnormal involuntary movements ("spontaneous dyskinesias") in the normal elderly.

Advancing age has been associated with increased prevalence of abnormal involuntary movements in neuroleptic-treated patients. In order to investigate the possibility that the aging process itself might produce involuntary movements clinically indistinguishable from tardive dyskinesia, a group of healthy elderly volunteers were systematically examined. A 4% prevalence rate of mild involuntary movements was found, suggesting that the aging process itself is not likely to produce dyskinesias without other contributing factors coming into play.

Aged↗
PubMed1982

A prospective study of tardive dyskinesia development: preliminary results.

Preliminary findings from a prospective study of tardive dyskinesia (TD) development in a population of psychiatric patients suggest a TD incidence of 12% after 4 years of cumulative neuroleptic exposure. No cases of abnormal involuntary movements that might be mistaken for TD have been found in patients with no history of neuroleptic exposure. Early findings with regard to risk factors are discussed.

Adolescent↗
PubMed1981

Clozapine: plasma levels and prolactin response.

Serial plasma clozapine levels and serum prolactin levels were determined in two schizophrenic patients receiving clozapine, a novel antipsychotic drug. Despite marked therapeutic response and substantial clozapine blood levels, prolactin levels obtained 11--12 h after the last oral dose were unaffected or only minimally elevated. This confirms previous evidence of clozapine's unusual characteristics.

Adult↗
PubMed1981

Familial occurrence of tardive dyskinesia.

Tardive dyskinesia remains a poorly understood consequence of neuroleptic treatment for psychiatric illness. To date, there have been no reports in the literature regarding the presence of dyskinetic symptomatology in first degree relatives or other family members. The following two cases reveal the development of abnormal involuntary movement in brothers with similar mental illness and treatment histories, and suggest the importance of examining neuroleptically treated relatives of an affected individual for dyskinesia and may suggest a genetic factor in vulnerability.

Adult↗
PubMed1980

Can schizophrenia with premorbid asociality be genetically distinguished from the other forms of schizophrenia?

Sufficient data exist to establish a genetic basis for some forms of schizophrenia. However, genetic factors may not account for all the variance, and subtle forms of central nervous system (CNS) damage may have etiological significance for some schizophrenic subtypes. One such subtype may be chronic schizophrenia with premorbid asociality (SPA). To test this hypothesis, the risk of schizophrenia among relatives of probands who did or did not meet the criteria for SPA was examined. The incidence of schizophrenia in the relatives of SPA probands was lower than that in the relatives of non-SPA probands. This difference approached but did not reach statistical significance. Because most studies have found a higher familial genetic loading in chronic forms of schizophrenia, the apparently lower incidence of disorder in relatives of chronic schizophrenics with premorbid asociality seems to be a heuristic lead worth pursuing.

Antisocial Personality Disorder↗
PubMed1979

Relationship between the B-mitten EEG pattern and tardive dyskinesia. A pilot control study.

The identification of patients at high risk for the development of tardive dyskinesia (TD) is a major problem in psychopharmacology. We found a possible relationship between the subcortical B-mitten EEG pattern and TD. Twenty-one TD pateints were matched on a number of relevant variables with 21 patients without TD. Ninety-five percent of the TD patients had mittens, compared to 33.3% of controls. The results suggest that the mitten dysrhythmia may be a risk factor for the development of TD. Additional findings suggest that among TD patients, mittens are differentially more frequent in younger (93.1%) as opposed to older (0.0%) subjects.

Adolescent↗
PubMed1979

Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.

To test the clinical efficacy of low dose fluphenazine decanoate (1.25 mg to 5.0 mg biweekly), we carried out two separate experiments: (1) an open trial in 57 schizophrenic outpatients, lasting 6 months; (2) a double-blind, placebo-controlled discontinuation study in a subgroup of patients who maintained good remission throughout the entire 6-month open trial. The results suggest that lower doses of fluphenazine decanoate than those usually used may be effective in preventing psychotic relapse while keeping total cumulative dosage to a minimum.

Aftercare↗